Clinical Trials Browser

Terminated × Neoplasm Metastasis × Albumin-Bound Paclitaxel × Clear all

Melanoma, Neoplasm Metastasis, Sarcoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04983407 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Phase 1/2 Terminated

34 enrolled

Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT02715804 2020-07-14

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Phase 3 Terminated

492 enrolled 16 charts

Gastrointestinal

Neoplasm Metastasis, Carcinoma, Pancreatic Ductal

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT00140140 2019-11-26

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Phase 1/2 Terminated

16 enrolled 21 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00281528 2019-11-22

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Phase 2 Terminated

208 enrolled 23 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Phase 1 Terminated

5 enrolled

BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

NCT02076243 2017-10-25

Treatment With Nab-paclitaxel in Cutaneous SCC

Phase 2 Terminated

2 enrolled 6 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT00607438 2012-05-11

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2 Terminated

16 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

Clinical Trials

MODULATE

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Safety Study of SEA-CD40 in Cancer Patients

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Treatment With Nab-paclitaxel in Cutaneous SCC

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer